Researchers reported on the results of the recent open-label DoxyPEP trial at the 24th International AIDS Conference. They found that among TGW and MSM who are taking HIV PrEP or are living with HIV, a single 200-mg dose of doxycycline PEP reduced the incidence of chlamydia, gonorrhea, and early syphilis by 65%.
The trial randomly assigned TGW and MSM who were on HIV PrEP or were living with HIV to either doxycycline or placebo within 72 hours of condomless sex. All participants had a history of chlamydia, gonorrhea, or early syphilis in the past year. The trial was stopped early after a planned interim analysis revealed that the doxycycline group had substantially fewer STIs than did the control group.
The researchers caution that the participants had a very high rate of new STIs and are a limited population.
Learn more about doxycycline.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L. Windle. Rapid Rx Quiz: Sexually Transmitted Infection Drug Treatments - Medscape - Nov 18, 2022.